Hepatitis C screening

Hepatitis Main Page

Hepatitis C

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology & Demographics

Risk Factors

Screening

Differentiating Hepatitis C from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Hepatitis C screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis C screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis C screening

CDC on Hepatitis C screening

Hepatitis C screening in the news

Blogs on Hepatitis C screening

Directions to Hospitals Treating Hepatitis C

Risk calculators and risk factors for Hepatitis C screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Yazan Daaboul, Serge Korjian

## Overview[edit | edit source]

People living in regions with high HCV prevalence and who have engaged in high-risk activities should be screened. Screening by serological testing, confirmed by nucleic acid amplification (NAT) for HCV RNA, is required. Additionally, screening for other bloodborne infections, such as HBV and HIV, is required once the diagnosis is made. The ideal frequency of testing in these patients is unclear and should be individualized according to the frequency of exposure to risk.

## Screening[edit | edit source]

### Initial Testing[edit | edit source]

Screening for HCV is performed by HCV serological testing.[1] In patients who test positive, a confirmation for chronic HCV status is required by nucleic acid amplification (NAT) or HCV RNA. HCV RNA may be directly tested in immunocompromised patients or patients who already had spontaneous or treatment-related clearance.[1]

Screening for other infections, such as HBV and HIV, is also indicated when patients are identified as HCV-positive. In some endemic areas and high-risk populations, screening for tuberculosis (TB) is also warranted.[1]

### Interpretation of Screening Results[edit | edit source]

* If an anti-HCV test is negative and patients are suspected to have liver disease, a follow-up HCV antibody or HCV RNA test is recommended if HCV exposure occurs within 6 months.[1]

* If an anti-HCV test is positive but HCV RNA is negative, patients have no evidence of active infection.[1]

* If an anti-HCV test is positive and HCV RNA is positive, a diagnosis of HCV infection is made. Quantitative HCV RNA tests should be performed before initiation of antiviral therapy to document baseline levels of viremia. Additionally, HCV genotyping is recommended to guide therapy.[1]

### Frequency of Screening[edit | edit source]

The ideal frequency of testing in patients is unclear and should be individualized according to frequency of exposure to risk. In patients who use intravenous drugs or HIV-positive men who have unprotected sex with men, annual screening may be considered.[2]

## Summary of Screening Recommendations[edit | edit source]

### American Association for the Study of Liver Disease (AASLD) - Infectious Diseases Society of America (IDSA) "Recommendations for Testing, Managing, and Treating Hepatitis C": 2014[1][edit | edit source]

According to the AASLD - IDSA recommendations in 2014, the following patients should be screened for HCV:

* People born between 1945 and 1965

#### Risk Behaviors[edit | edit source]

* Injection-drug use (current or ever, including those who injected once)
* Intranasal illicit drug use

#### Risk Exposures[edit | edit source]

* Long-term hemodialysis (ever)
* Getting a tattoo in an unregulated setting
* Healthcare, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-infected blood
* Children born to HCV-infected women
* Prior recipients of transfusions or organ transplants, including persons who:
* were notified that they received blood from a donor who later tested positive for HCV infection
* received a transfusion of blood or blood components or underwent an organ transplant before July 1992
* received clotting factor concentrates produced before 1987
* were ever incarcerated

#### Other Medical Conditions[edit | edit source]

* HIV infection
* Unexplained chronic liver disease and chronic hepatitis including elevated alanine aminotransferase levels

### World Health Organization "Guidelines for the Screening, Care, and Treatment of Persons with HCV": 2014[edit | edit source]

Generally, the World Health Organization (WHO) Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection[1] published on April 2014 recommends HCV screening for all people living in regions of high HCV prevalence with positive history for risk exposure and behavior.[1]

Screening includes:[1]

* Persons who received medical or dental interventions in health-care settings where infection control practices are substandard
* Persons who received blood transfusions prior to the time when serological testing of blood donors for HCV was initiated
* Persons who received blood transfusions in countries where serological testing of blood donations for HCV is not routinely performed
* Persons who inject drugs (PWID)
* Persons who have had tattoos, body piercings, or scarification procedures are done where infection control practices are substandard
* Persons with HIV infection
* Persons who have used intranasal drugs
* Prisoners and previously incarcerated persons

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "World Health Organization (WHO) Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection" (PDF). World Health Organization. WHO. April 2014. Retrieved July 27, 2014.
2. ↑ Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA (2014). "Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America". Clin Infect Dis. 58 (1): 1–10. doi:10.1093/cid/cit757. PMID 24343580.CS1 maint: Multiple names: authors list (link)